Dopamine, prefrontal cortex and working memory functioning in schizophrenia

Pharmacopsychiatry

Volumn 40, Issue SUPPL. 1, 2007, Pages

  Meisenzahl, E M ^a   Scheuerecker, J ^a   Schmitt, G J S ^a   Moller H J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CATECHOL METHYLTRANSFERASE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; LEVODOPA; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE;

ATTENTION DEFICIT DISORDER; BRAIN REGION; CLINICAL FEATURE; COGNITION; CONFERENCE PAPER; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DYSMETRIA; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC ASSOCIATION; HUMAN; LEARNING; NERVE DEGENERATION; NEUROIMAGING; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PHENYLKETONURIA; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VERBAL BEHAVIOR; WORKING MEMORY;

EID: 37549056532     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-992132     Document Type: Conference Paper

References (166)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998; 155: 761-767
2. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97 (14): 8104-8109
3. Abler B, Erk S, Waiter H. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebocontrolled fMRI study. Psychopharmacology 2007; 191 (3): 823-833
4. Addington J, Addington D. Cognitive functioning in first-episode schizophrenia. J Psychiatry Neurosci 2002; 27 (3): 188-192
5. Andreasen N. Negative symptoms in schizophrenia, definition and reliability. Arch Gen Psychiatry 1982; 39 (7): 784-788
6. Andreasen NC, Flashman L, Flaum M, Arndt S, Swayze V, O'Leary DS et al. Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. JAMA 1994; 272 (22): 1763-1769
7. Andreasen NC, Nopoulos P, O'Leary DS, Miller DD, Wassink T, Flaum M. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol Psychiatry. 1999; 46 (7): 908-920
8. Andreasen NC, Nasrallah HA, Dunn VD et al. Structural abnormalities in the frontal system in schizophrenia: A magnetic resonance imaging study. Arch Gen Psychiatry 1986; 43: 136-144
9. Andreasen NC, Paradiso S, O'Leary DS. Cognitive dysmetria as an integrative theory of schizophrenia: A dysfunction in cortical-cerebellar circuitry? Schizophr Bull 1998; 24: 203-218
10. Baddeley A. Wm. Oxford University Press 1986
11. Baddeley A. Working Memory. Science 1992; 255: 556-559
12. Baker K, Baldeweg T, Sivagnanasundaram S, Scambler P, Skuse D. COMT Val108/158 Met modifies mismatch negativity and cognitive function in 22q11 deletion syndrome. Biol Psychiatry 2005; 58 (1): 23-31
13. Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P. The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol 2001; 11: 449-455
14. Barch D, Carter C, Braver T, Sabb F, MacDonald AR, Noll D et al. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry 2001; 58 (3): 280-288
15. Bender W, Albus M, Möller HJ, Tretter F. Towards systemic theories in biological psychiatry. Pharmacopsychiatry 2006; 39 (1): 4-9
16. Bertolino A, Blasi G, Caforio G, Latorre V, DeCandia M, Rubino V et al. Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine. Biol Psychiatry 2004; 56(3): 190-197
17. Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X et al. Neurocognitive correlates of the COMT Val (158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002; 52 (7): 701-707
18. Braver TS, Cohen JD. Dopamine, cognitive control, and schizophrenia: the gating model. Prog Brain Res 1999; 121: 327-349
19. Broadbent D. Perception and communication. Pergamon: Oxford 1985
20. Bruder GE, Keilp JG, Xu H, Shikhman M, Schori E, Gorman J et al. Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol Psychiatry 2005; 58(11): 901-907
21. Callicott JH, Ramsey NF, Tallent K, Bertolino A, Knable MB, Coppola R, Goldberg T, Gelderen P van, Mattay VS, Frank JA, Moonen CT, Weinberger DR. Functional magnetic resonance imaging brain mapping in psychiatry: methodological issues illustrated in a study of working memory in schizophrenia. Neuropsychopharmacol 1998; 18 (3): 186-196
22. Callicott J, Mattay V, Verchinski B, Marenco S, Egan M, Weinberger D. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry 2003; 160 (12): 2209-2215
23. Callicott JH, Bertolino A, Mattay VS, Langheim F, Duyn J, Coppola R et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 2000; 10 (11): 1078-1092
24. Cannon TD, Zorrilla LE, Shtasel D, Gur RE, Gur RC, Marco EJ et al. Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry. 1994; 51 (8): 651-661
25. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry. 2006; 39 (1): 10-14
26. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179-186
27. Chafee MV, Goldman-Rakic PS. Inactivation of parietal and prefrontal cortex reveals interdependence of neural activity during memory-guided saccades. J Neurophysiol 2000; 83 (3): 1550-1566
28. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3 (8): 1607-1619
29. Christensen J, Holcomb J, Garver DL. State-related changes in cerebral white matter may underlie psychosis exacerbation. Psychiatry Res 2004; 130(1): 71-78
30. Cohen JD, Braver TS, Brown JW. Computational perspectives on dopamine function in prefrontal cortex. Curr Opin Neurobiol 2002; 12 (2): 223-229
31. Cohen JD, Dunbar K, MacLelland JL. On the control of automatic processes: A parallel distributed processing model of the Stroop effect. Psychol Rev 1990; 97 (3): 332-361
32. Cohen JD, Servan-Schreiber D. Context, cortex and dopamine: A connectionist approach to behavior and biology in schizophrenia. Psychol Rev 1992; 99: 45-77
33. Daniel DG, Weinberger DR, Jones DW, Zigun JR, Coppola R, Handel S et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 1991; 11: 1907-1917
34. Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 1997; 23 (2): 167-174
35. Davis JM, Andriukaitis S. The natural course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol 1986; 6: 2-10
36. Dayan P, Williams J. Putting the coputation back into computational modeling. Pharmacopsychiatry 2006; 39 (1): 50-51
37. Deco G. A dynamical model of event-related FMRI signals in prefrontal cortex: predictions for schizophrenia. Pharmacopsychiatry 2006; 39 (1): 65-67
38. Diamond A, Goldman-Rakic PS. Comparison of human infants and rhesus monkeys on Piaget's AB task: evidence for dependence on dorsolateral prefrontal cortex. Exp Brain Res 1989; 74 (1): 24-40
39. Diamond A, Prevor MB, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev 1997; 62 (4): 1-208
40. Doran AR, Boronow J, Weinberger DR, Wolkowitz OM, Breier A, Pickar D. Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. Neuropsychopharmacology. 1987; 1(1): 25-32
41. Dreher JC, Guigon E, Burnod Y. A model of prefrontal cortex dopaminergic modulation during the delayed alternation task. J Cogn Neurosci 2002; 14 (6): 853-865
42. Fahim C, Stip E, Mancini-Marie A, Gendron A, Mensour B, Beauregard M. Differential hemodynamic brain activity in schizophrenia patients with blunted affect during quetiapine treatment. J Clin Psychophamacology 2005; 25 (4): 367-371
43. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49 (7): 538-544
44. 2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 1987; 44: 671
45. 2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron Emission Tomography study with raclopride. Arch Gen Psychiatry 1990; 47: 213-219
46. 2 receptors from plasma levels. Psychopharmacology 2000; 149 (1): 1-5
47. Floresco SB, Magyar O. Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology 2006; 188 (4): 567-585
48. Frank MJ, Loughry B, O'Reilly RC. Interactions between frontal cortex and basal ganglia in working memory: a computational model. Cogn Affect Behav Neurosci 2001; 1 (2): 137-160
49. Gallinat J, Bajbouj M, Sander T, Schlattmann P, Xu K, Ferro EF et al. Association of the G1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biol Psychiatry 2002; 54 (1): 40-48
50. Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry 2005; 58 (1): 62-66
51. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of casecontrol and family-based studies. Am J Psychiatry 2003; 160 (3): 469-476
52. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS et al. Executive subprocesses in working memory-relationship to catechol-Omethyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003; 60: 889
53. Goldberg TE, Gold JM, Greenberg R, Griffin S, Schulz SC, Pickar D et al. Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry 1993; 150 (9): 1355-1362
54. Goldman-Rakic P. Handbook of Physiology: the Nervous System (vol 5) Circuitry of primate prefrontal cortex and regulation of behaviour by representational memory. American Physiological Society 1987; 373-417
55. Good MF, Kiss I, Buiteman C, Woodley H, Ruui Q, Whitehorn D, Kopala L. Improvement in cognitive functioning in patients with first- episode psychosis during treatment with quetiapine: an interim analysis. Brit Jour of Psych 2002; 43: 45-49
56. Gorelova N, Seamans JK, Yang CR. Mechanisms of dopamine activation of fastspiking interneurons that exert inhibition in rat prefrontal cortex. J Neurophysiol 2002; 88 (6): 3150-3166
57. Gourovitch M, Goldberg T. Schizophrenia: A neuropsychological perspective, chapter cognitive deficits in schizophrenia: Attention, executive functions, memory and language processing. Wiley: Chichester 1996; 71-86
58. Green M. Schizophrenia from a neurocognitive perspective. Allyn and Bacon: Boston 1998
59. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000; 26 (1): 119-136
60. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153 (3): 321-330
61. Gruber AJ, Dayan P, Gutkin BS, Solla SA. Dopamine modulation in the basal ganglia locks the gate to working memory. J Comput Neurosci 2006; 20(2): 153-166
62. Gur RE, Cowell PE, Latshaw A, Turetsky BI, Grossman RI, Arnold SE et al. Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Arch Gen Psychiatry 2000; 57 (8): 761-768
63. Heiden U an der. Schizophrenia as a dynamical disease. Pharmacopsychiatry 2006; 39 (1): 36-42
64. Hazy TE, Frank MJ, O'Reilly RC. Banishing the homunculus: making wm work. Neuroscience 2006; 139 (1): 105-118
65. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151: 1409-1416
66. Hoffman RE, McGlashan TH. Using a speech perception neural network computer simulation to contrast neuroanatomic versus neuromodulatory models of auditory hallucinations. Pharmacopsychiatry 2006; 39(1): 54-64
67. Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry 2005; 162 (12): 2233-2245
68. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci 1999; 96 (23): 13432-13437
69. 99mTc]- TRODAT-1. Schizophr Res 2003; 65: 39-46
70. Hutton SB, Puri BK, Duncan LJ, Robbins TW, Barnes TR, Joyce EM. Executive function in first-episode schizophrenia. Psychol Med 1998; 28 (2): 463-73
71. Jahn T, Cohen R, Mai N, Ehrensperger M, Marquardt C, Nitsche N et al. Untersuchung der fein- und grobmotorischen Dysdiadochokinese schizophrener Patienten: Methodenentwicklung und erste Ergebnisse einer computergestützten Mikroanalyse. Z Klin Psychol 1995; 24: 300-315
72. Johnstone EC. Disabilities and circumstances of schizophrenic patients: A follow-up study. Br J Psychiatry 1995; 159: 5-46
73. Jones HM, Brammer MJ, O'Toole M, Taylor T, Ohlsen RI, Brown RG et al. Cortical effects of quetiapine in first-episode schizophrenia: a preliminary functional magnetic resonance imaging study. Biol Psychiatry 2004; 56: 938-942
74. Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wüstenberg T, Villringer A et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology 2006a; 187 (2): 222-228
75. Juckel G, Schlagenhauf F, Koslowski M, Wüstenberg T, Villringer A, Knutson B et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006b; 29 (2): 409-416
76. 2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosi 2000; 25 (2): 161-166
77. Knutson B, Adams CM, Fong GW, Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci 2001; 21 (16): RC159
78. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron 1998; 21 (3): 467-476
79. Koob GF, Moal M Le. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278 (5335): 52-58
80. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O et al. Striatal Dopamine Transporter Binding in Neuroleptic-Naive Patients with Schizophrenia Studied with Positron Emission Tomography. Am J Psychiatry 2000; 157: 269-271
81. Laruelle M, Abi-Dargham A, Dyck CH van, Gil R, D'Souza CD, Erdos J et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-9240
82. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999; 46 (1): 56-72
83. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20 (3): 423-451
84. 123I] β-CIT. Biol Psychiatry 2000; 47: 371-379
85. Lavalaye J, Linszen DH, Booij J, Dingemans PMAJ, Reneman L, Habraken JBA et al. Dopamine transporter density in young patients with schizophrenia assessed with FP-CIT SPECT. Schizophrenia Res 2001; 47: 59-67
86. Laywer G, Nyman H, Agartz I, Amborg S, Jönsson EG, Sedvall GC et al. Morphological correlates to cognitive dysfunction in schizophrenia as studied with Bayesian regression. BMC Psychiatry 2006; 6: 31
87. Lewis DA. Development of the prefrontal cortex during adolescence: Insights into vulnerable neural circuits in schizophrenia. Neuropsychopharmacology 1997; 16: 358-398
88. Lidow MS, Koh PO, Amsten AFT. D1 dopamine receptors in the mouse prefrontal cortex: Immunocytochemical and cognitive neuropharmacological analyses. Synapse 2003; 47 (2): 101-108
89. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 1999; 46 (6): 729-739
90. Lieberman J, Bogerts B, Degreef G, Ashtari M, Lantos G, Alvir J. Qualitative assessment of brain morphology in acute and chronic schizophrenia. Am J Psychiatry 1992; 149: 784-794
91. Lieberman J, Kane J, Woerner M, Alvir J, Borenstein M, Novacenko H. Prediction of relapse in schizophrenia. Clin Neuropharmacol 1990; 13: 434-435
92. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997; 17: 205-229
93. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149: 1183-1188
94. Lynd-Balta E, Haber SN. The organization of midbrain projections to the striatum in the primate: ensorimotor-related striatum versus ventral striatum. Neuroscience 1994a; 59 (3): 625-640
95. Lynd-Balta E, Haber SN. The organization of midbrain projections to the ventral striatum in the primate. Neuroscience 1994b; 59 (3): 609-623
96. Maher BA, Manschreck TC, Woods BT, Yurgelun-Todd DA, Tsuang MT. Frontal brain volume and context effects in short-term recall in schizophrenia. Biol Psychiatry 1995; 37 (3): 144-150
97. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002; 159 (4): 652-654
98. Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E et al. Schizophrenic subjects show aberrant fmri activation of dorsolateral prefrontal cortex and basal ganglia during wm performance. Biol Psychiatry 2000; 48 (2): 99-00
99. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2001; 58(2): 148-157
100. Matsumoto M, Weickert CS, Beltaifa S, Kolachana B, Chen JS, Hyde TM et al. Catechol O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology 2003; 28: 1521
101. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003; 100 (10): 6186-6191
102. MacClure RK, Phillips I, Jazayerli R, Barnett A, Coppola R, Weinberger DR. Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment. Psychiatry Res 2006; 148 (2-3): 121-132
103. Meisenzahl E, Scheuerecker J, Zipse M, Ufer S, Wiesmann M, Frodl T et al. Effects of treatment with the atypical neuroleptic quetiapine on wm function: an functional mri follow-up investigation. Europ Arch Psychiatry Clin Neurosci 2006; 256 (8): 522-531
104. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25 (3): 390-392
105. Menon RS. Imaging function in the working brain with fmri. Current Opinion in Neurobiology 2001; 11 (5): 630-636
106. Möller H. Can negative symptoms of schizophrenia be partially or totally controlled by antipsychotics? Eur Neuropsychopharmacol 1999; 9(5): 135-136
107. Norman KA, O'Reilly RC. Modeling hippocampal and neocortical contributions to recognition memory: A complementary learning systems approach. Psychol Rev 2003; 110: 611-646
108. Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 1984; 10 (2): 160-203
109. Perlstein W, Dixit N, Carter C, Noll D, Cohen J. Prefrontal cortex dysfunction mediates deficits in wm and prepotent responding in schizophrenia. Biol Psychiatry 2003; 53 (1): 25-38
110. Perry W, Light GA, Davis H, Braff DL. Schizophrenia patients demonstrate a dissociation on declarative and non-decclarative memory test. Schizophr Res 2000; 46: 167-174
111. Pessoa L, Gutierrez E, Bandettini P, Ungerleider L. Neural correlates of visual wm: fMRI amplitude predicts task performance. Neuron 2002; 35 (5): 975-987
112. Petrides M. The role of the mid-dorsolateral prefrontal cortex in wm. Exp Brain Res 2000; 133: 44-54
113. 2 receptor occupancy in vivo and response to the new antipsychotic risperidone. Br J Psychiatry 1994; 163: 833-834 Erratum in: Br J Psychiatry 1994 Feb; 164 270
114. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with hizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001; 26 (2): 137-149
115. Raine A, Lencz T, Reynolds GP, Harrison G, Sheard C, Medley I et al. An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. Psychiatry Res 1992; 45 (2): 123-137
116. Reeve WV, Schandler SL. Frontal lobe functioning in adolescents with attention deficit hyperactivity disorder. Adolescence 2001; 36: 749-765
117. Robinson D, Woerner M, Alvir J, Bilder R, Goldman R, Geisler S et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544-549
118. Sakai K, Rowe JB, Passingham RE. Active maintenance in prefrontal area 46 creates distractor-resistant memory. Nat Neurosci 2002; 5 (5): 479-484
119. Sawaguchi T, Matsumura M, Kubota K. Effects of dopamine antagonists on neuronal activity related to a delayed response task in monkey prefrontal cortex. J Neurophysiol 1990; 63 (6): 1401-1412
120. Scheuerecker J, Ufer S, Zipse M, Wiesmann M, Brückmann H, Koutsouleris M et al. Cerebral changes and cognitive dysfunctions in medication- free schizophrenia- an fMR1 study. J Psychiatry Res 2007
121. Schlösser R, Wagner G, Köhler S, Sauer H. Schizophrenie als Diskonnektionssyndrom. Radiologe 2005; 45 (2): 137-143
122. 99mTc]-TRODAT-1- SPECT-Study. Europ Neuropsychopharmacology 2000; 10 (3): 324
123. Schmitt GJE, Frodl T, Dresel S, Möller H-J, Meisenzahl EM. Striatal dopaminergic synapses in drug naive schizophrenics. World J Biol Psychiatry 2001; 2(1): 93
124. 2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine. J Psychopharmacol 2002; 16 (3): 200-206
125. 99mTc]TRODAT-1. J Psychopharmacology 2005; 19: 488-493
126. Schmitt GJE, Frodl T, Dresel S, Fougère C la, Bottlender R, Koutsouleris N et al. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 2006; 256: 115-121 Epub 2005 Nov 15
127. Schmitt GJE, Fougère C la, Dresel S, Frodl T, Hahn K, Möller H-J et al. Dualisotope SPECT imaging of striatal dopamine in first-episode, drug naïve schizophrenic patients. Schizophrenia Res 2007, (submitted)
128. Schultz W, Apicella P, Ljungberg T. Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task. J Neurosci 1993; 13 (3): 900-913
129. Schwegler H. Phenomenological modelling of some mechanisms in schizophrenia. Pharmacopsychiatry 2006; 39 (1): 43-49
130. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47 (1): 27-38
131. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the chizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 1995; 52 (10): 805-818 ; discussion 819-820.
132. Shenton ME, Dickey CC, Frumin M, MacCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49 (1-2): 1-52
133. Shifman S, Bronstein M, Sternfeld M, Pisanté-Shalom A, Lev-Lehman E, Weizman A et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296
134. Stip E, Chouinard S, Boulay LJ. On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29 (2): 219-232
135. Stip E, Fahim C, Mancini-Marie A, Bentaleb LA, Mensour B, Mendrek A et al. Restoration of frontal activation during a treatment with quetiapine: a fMRI study of blunted affect in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29 (1): 21-26
136. Sullivan EV, Shear PK, Lim KO, Zipursky RB, Pfefferbaum A. Cognitive and motor impairments are related to gray matter volume deficits in schizophrenia. Biol Psychiatry 1996; 39 (4): 234-240
137. Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry 1996; 153: 519-525
138. Tamagaki C, Sedvall GC, Jönsson EG, Okugawa G, Hall H, Pauli S et al. Altered white matter/gray matter proportions in the striatum of patients with schizophrenia: a volumetric MRI study. Am J Psychiatry 2005; 162 (12): 2315-2321
139. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with luorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992; 49 (7): 522-530
140. Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ. Catechol-Omethyltransferase inhibition improves set shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 2004; 24: 5331
141. Tretter F, Scherer J. Schizophrenia, neurobiology and the methodology of systemic modeling. Pharmacopsychiatry 2006; 39 (1): 26-35
142. Urban NN, González-Burgos G, Henze DA, Lewis DA, Barrionuevo G. Selective reduction by dopamine of excitatory synaptic inputs to pyramidal neurons in primate prefrontal cortex. J Physiol 2002; 539 (3): 707-712
143. Haren NEM van, Pol HEH, Schnack HG, Cahn W, Mandl RCW, Collins DL et al. Focal gray matter changes in schizophrenia across the course of the illness: A 5- Year Follow-Up Study. Neuropsychopharmacology 2007, epub ahead of print
144. Velligan DI, Bow-Thomas CC. Executive function in schizophrenia. Semin Clin Neuropsychiatry 1999; 4 (1): 24-33
145. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Amsten AFT. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in wm. Nat Neurosci 2007; 10 (3): 376-384
146. Volz H, Gaser C, Hager F, Rzanny R, Ponisch J, Mentzel H et al. Decreased frontal activation in schizophrenics during stimulation with the continuous performance test - a functional magnetic resonance imaging study. Europ Psychiatry 1999; 14 (1): 17-1 24
147. Waelti P, Dickinson A, Schultz W. Dopamine responses comply with basic assumptions of formal learning theory. Nature 2001; 412 (6842): 43-48
148. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50 (11): 825-844
149. Weinberger DR, Torrey EF, Neophytides AN, Wyatt RJ. Structural abnormalities in the cerebral cortex of chronic schizophrenic patients. Arch Gen Psychiatry. 1979; 36 (9): 935-939
150. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50: 825
151. Weinberger DR. Schizophrenia and the frontal lobe. TINS 1998; 11: 367-370
152. Weinberger DR. From neuropathology to neurodevelopment. Lancet 1995; 346: 552-557
153. Weinberger DR, Berman K. Prefrontal function in schizophrenia: confounds and controversies. Philos Trans R Soc Lond B Biol Sci 1996; 351 (1346): 1495-1503
154. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44 (7): 660-669
155. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376 (6541): 572-575
156. Williams HJ, Glaser B, Williams NM, Norton N, Zammit S, MacGregor S et al. No association between schizophrenia and polymorphisms in COMT in two large samples. Am J Psychiatry 2005; 162 (9): 1736-1738
157. Winstanley CA, Theobald DE, Dalley JW, Cardinal RN, Robbins TW. Double dissociation between serotonergic and dopaminergic modulation of medial prefrontal 31 and orbitofrontal cortex during a test of impulsive choice. Cereb Cortex 2006; 16: 106-114
158. Winterer G, Egan MF, Kolachana BS, Goldberg TE, Coppola R, Weinberger DR. Prefrontal electrophysiologic "noise" and catechol-O- methyltransferase genotype in schizophrenia. Biol Psychiatry 2006; 60 (6): 578-584
159. Winterer G, Goldman D. Genetics of human prefrontal function. Brain Res Brain Res Rev 2003; 43 (1): 134-163
160. Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci 1996; 19: 319-340
161. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry. 1992; 49 (12): 959-965
162. Wyatt RJ. Early intervention for schizophrenia: can the course of the illness be altered. Biol Psychiatry 1995; 38: 1-3
163. 3 receptor and transporter binding in drug-naïve patients with schizophrenia: A Dual-Isotope SPECT study. Am J Psychiatry 2004; 161: 1496-1498
164. Yang P, Chung LC, Chen CS, Chen CC. Rapid improvement in academic grades following methylphenidate treatment in attention-deficit hyperactivity disorder. Psychiatry Clin Neurosci 2004; 58: 37-41
165. Zahrt J, Taylor JR, Mathew RG, Arnsten AF. Supranormal Stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial wm performance. J Neurosci 1997; 17 (21): 8528-8535
166. Zuffante P, Leonard CM, Kuldau JM, Bauer RM, Doty EG, Bilder RM. Wm deficits in schizophrenia are not necessarily specific or associated with MRI-based estimates of area 46 volumes. Psychiatry Res 2001; 108 (3): 187-209